Understanding how a protein called Merlin affects tumor growth in neurofibromatosis type 2.
Official title: Function of NF2/Merlin in regulation of the Hippo/Salvador/Warts growth control pathway
Funded at University of Chicago · NIH-10932325 · Data updated 2026-11-12
This study is looking at how a protein called Merlin helps control tissue growth and how changes in this protein can lead to tumors in people with neurofibromatosis type 2, with the goal of finding new treatments for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $477,946 |
| NIH project number | 5R01NS034783-24 |
| Project ID | NIH-10932325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 2, particularly those experiencing tumor growth.
✕Less likely to help
Patients without neurofibromatosis type 2 or those not affected by related tumor growth may not benefit from this research.
What this research studies
This research investigates the role of the Merlin protein in regulating the Hippo signaling pathway, which is crucial for controlling tissue growth. By studying both fruit flies and mammalian systems, the researchers aim to uncover how mutations in Merlin lead to tumor formation in conditions like neurofibromatosis type 2. The project focuses on identifying the specific proteins that interact with Merlin and how these interactions can influence disease outcomes. This knowledge could help in developing targeted therapies for patients affected by this condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating tumors associated with neurofibromatosis type 2.
How similar studies have gone: Previous studies have shown success in understanding the Hippo pathway's role in tumor biology, indicating that this research builds on established findings.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Fehon, Richard G — University of Chicago
- Study coordinator: Fehon, Richard G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.